EU Pharma Industry Must Now Start Assessing Excipient Risks
This article was originally published in The Gold Sheet
An industry “how to” guide that aims to help pharmaceutical manufacturers comply with the EU’s new risk assessments for excipients says that implementation will be difficult. The new requirements took effect on March 21.
You may also be interested in...
Officials from the US Food and Drug Administration cited their reasons for refusing to review new applications for companies with unresolved data integrity failures.
Action responds to methanol contamination in hand sanitizers manufactured in Mexico and marketed in the US under numerous brands that followed a loosening standards for the products to drive a swift increase in production and meet surging demand during the coronavirus pandemic.
New import alert category and border testing required after reduced standards put dangerous sanitizers into hands of US consumers.